Supplementation With Salicornia Extract Rich in Polyphenols (B-Salicornia) to Improve Vascular Health in Patients With Dyslipidemia Who Are Not Candidates for Drug Treatment (Low to Moderate Risk)

Researchers will compare the treatment group taking the B-Salicornia supplement plus standard medical treatment with a control group receiving standard medical treatment.

Participants will:

• Take 500 mg of the B-Salicornia dietary supplement daily for three months.
• Visit the hospital at the beginning and end of the trial for a physical examination and routine blood tests, including vascular parameters such as lipids and homocysteine.

Inclusion criteria

• Participants aged 40 to 65
• Newly diagnosed dyslipidemia (two years) with SCORE ≥1 - <5 (LDL 116 - <190 mg/dL): Moderate Risk
• No indication for pharmacological treatment in primary prevention.
• Possibility of performing analytical controls at the beginning/end of the study.
• Willingness and capacity to give informed consent.

Exclusion criteria

• Participants with vascular risk requiring pharmacological treatment or high/very high vascular risk.
• Participants in secondary prevention.
• Hyperthyroidism according to the researcher's criteria.
• Taking vitamin B supplements and/or supplements containing polyphenols in the 30 days prior to the screening visit (at the researcher's discretion).
• Serious illness with a life expectancy of less than three months.
• Known allergies or intolerance to halophytic plants.
• Pregnant or breastfeeding women.
• Presence of active neoplastic disease.
• Having participated in another clinical trial with medicines in the 30 days prior to the screening visit, or intending to do so during your participation in this study.
• Regular consumption of halophyte plants.
• Participants who, in the researcher's opinion, are not able to comply with the study protocol.